# Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

> **NCT06846606** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Auron Therapeutics, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Relapsed Acute Myeloid Leukemia (AML)
- Refractory Acute Myeloid Leukemia (AML)
- Relapsed/Refractory AML
- Relapsed Myelodysplastic Syndromes
- Refractory Myelodysplastic Syndromes
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** AUTX-703

## Key facts

- **NCT ID:** NCT06846606
- **Lead sponsor:** Auron Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-04
- **Final completion:** 2028-06
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06846606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06846606, "Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06846606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*